Immunotherapy

Adding Indoximod to Pembrolizumab Boosts Immune Response in Melanoma

Phoebe Starr

June 2017, Vol 8, No 3 - Immunotherapy

Washington, DC—Adding the investigational drug indoximod, an indole­amine 2,3-dioxygenase (IDO) pathway inhibitor, to the checkpoint inhibitor pembrolizumab (Keytruda) led to higher response rates in patients with advanced melanoma than what is reported with pembrolizumab monotherapy, said lead investigator Yousef Zakharia, MD, Clinical Assistant Professor of Internal Medicine, Division of Hema­tology, Oncology and Blood and Marrow Transplantation, University of Iowa, Iowa City, at the 2017 American Association for Cancer Research meeting. [ Read More ]

Atezolizumab plus Bevacizumab Combo Shows Promise in Patients with Metastatic Kidney Cancer

Phoebe Starr

June 2017, Vol 8, No 3 - Immunotherapy

Orlando, FL—Atezolizumab plus bevacizumab showed encouraging responses as a first-line treatment of metastatic renal-cell carcinoma in a phase 2 trial. Although the trial failed to meet its primary end point of significant improvement in progression-free survival (PFS) compared with sunitinib, the combination did reduce the risk for death or disease progression by 36% in patients with elevated PD ligand 1 (PD-L1) expression. The median PFS was almost double in the PD-L1–positive group with atezolizumab plus bevacizumab versus sunitinib (14.7 months vs 7.8 months, respectively). [ Read More ]

Longest Follow-Up in Patients with NSCLC Who Responded to Immunotherapy with Nivolumab

Phoebe Starr

June 2017, Vol 8, No 3 - Immunotherapy

Washington, DC—In the longest follow-up on single-agent nivolumab (Opdivo) to date, 5-year overall survival was 16% in patients with advanced non–small-cell lung cancer (NSCLC) in the updated results of a phase 1b dose-ranging study (CA209-003). This represents a quadrupling of 5-year overall survival with standard platinum doublets, which is approximately 4% for patients with metastatic NSCLC. [ Read More ]

Immunotherapy with Nivolumab plus Ipilimumab Improves Outcomes in Metastatic Urothelial Cancer

Walter Alexander

April 2017, Vol 8, No 2 - Immunotherapy

National Harbor, MD—Results of a phase 1/2 study that investigated 2 dosing regi­mens of 2 immunotherapies—the PD-1 inhibitor nivolumab (Opdivo) plus the CTLA-4 inhibitor ipilimumab (Yervoy)—in patients with previously treated metastatic urothelial carcinoma showed higher response rates and longer median overall survival with the regimen of nivolumab 1 mg/kg plus ipilimumab 3 mg/kg than with the dosing of nivolu­mab 3 mg/kg plus ipilimumab 1 mg/kg. [ Read More ]

Urelumab Safe and Active as Monotherapy and in Combination with Nivolumab in Several Types of Cancer

Walter Alexander

April 2017, Vol 8, No 2 - Immunotherapy

National Harbor, MD—The investigational CD137 agonist urelumab, given as monotherapy and in combination with the anti–PD-1 monoclonal antibody nivolumab, demonstrated safety and, in some patients with hematologic and solid tumor malignancies, promising antitumor activity, according to results of 2 early-phase studies presented at the 2016 Society for Immunotherapy of Cancer annual meeting. [ Read More ]

Maximizing the Potential of Immunotherapy the Focus of Cancer Moonshot 2020

Wayne Kuznar

December 2016, Vol 7, No 11 - Immunotherapy

Washington, DC—The Cancer Moonshot 2020 program is exploring a new paradigm in cancer care by bringing clinical trials focused on immunotherapy to community and academic practices. This privately funded initiative seeks to conduct phase 2 clinical trials within the next 36 months in 20,000 patients with >20 tumor types at all stages of cancer, said Gary Palmer, MD, JD, MPH, Chief Medical Officer, President, GPS Operations, NantHealth, Culver City, CA, at the Sixth Annual Conference of the Association for Value-Based Cancer Care. [ Read More ]